The growing importance of lesion volume as a prognostic factor in patients with multiple brain metastases treated with stereotactic radiosurgery

David M. Routman1,2, Shelly X. Bian2, Kevin Diao2,3, Jonathan L. Liu4, Cheng Yu2, Jason Ye2, Gabriel Zada5 & Eric L. Chang2

1Department of Radiation Oncology, Mayo Clinic, Rochester, Minnesota
2Department of Radiation Oncology, Keck School of Medicine of USC, Los Angeles, California
3Harvard Medical School, Boston, Massachusetts
4Department of Radiology, Washington University, St. Louis, Missouri
5Department of Neurological Surgery, Keck School of Medicine of USC, Los Angeles, California

Abstract

Stereotactic Radiosurgery (SRS) is considered standard of care for patients with 1–3 brain metastases (BM). Recent observational studies have shown equivalent OS in patients with 5+ BM compared to those with 2–4, suggesting SRS alone may be appropriate in these patients. We aim to review outcomes of patients treated with SRS with 2–4 versus 5+ BM. This analysis included consecutive patients from 1994 to 2015 treated with SRS. Of 1017 patients, we excluded patients with a single BM and patients without adequate survival data, resulting in 391 patients. All risk factors were entered into univariate analysis using Cox proportional hazards model, and significant factors were entered into multivariate analysis (MVA). We additionally analyzed outcomes after excluding patients with prior surgery or whole-brain radiotherapy (WBRT). Median follow-up was 7.1 months. Median KPS was 90, mean age was 59, and most common histologies were melanoma and lung. Median tumor volume was 3.41 cc. Patients with 2–4 BM had a median OS of 8.1 months compared to 6.2 months for those with 5+ BM (P = 0.0136). On MVA, tumor volume, KPS, and histology remained significant for OS, whereas lesion number did not. Similar results were found when excluding patients with prior surgery or WBRT. Rather than lesion number, the strongest prognostic factors for patients undergoing SRS were tumor volume >10 cc, KPS, and histology. BM number may therefore not be the most important criterion for candidacy for SRS. Patients with 5 or more BM should be considered for SRS.

Introduction

Brain metastases (BM) develop in up to 20–40% of patients diagnosed with cancer, and the incidence is increasing as cancer patients are living longer with improving systemic therapy [1, 2]. Radiation therapy (RT) is an integral component of the treatment of BM to improve local control, and in certain instances, overall survival (OS). Whole-brain radiation therapy (WBRT) has traditionally been the standard for patients with multiple BM. However, there has been a trend toward increased use of stereotactic radiosurgery (SRS) for management of patients with single or <4 BM [3, 4].

The efficacy and toxicity of WBRT in comparison with and in addition to SRS have been evaluated in a randomized fashion and in a meta-analysis [5]. Recent trials have shown the addition of WBRT to SRS does not improve survival outcomes, and WBRT causes significant declines in neurocognition and overall quality of life (QOL) for patients with 1–3 BM [6, 7]. For example, Alliance trial N0574 randomized patients with 1–3 BM to SRS versus WBRT and found no statistically significant difference in median OS, 10.4 months versus 7.4 months, respectively (P = 0.92). While WBRT after SRS improved local and regional control, it had no impact...
Lesion Volume in SRS as Prognostic Factor

Methods

Study population

Institutional review board approval was obtained and retrospective review was performed of all consecutive patients with BM treated with SRS at our institution from 1994 to 2015. We included patients with two or more treated BM, and excluded patients who were missing critical baseline, treatment, or survival information. We additionally analyzed outcomes after excluding patients who were treated with prior neurosurgical resection or WBRT. We obtained patient and treatment information from electronic medical records and survival data from the institutional cancer registry.

Radiation delivery

All patients were treated with single-fraction Gamma Knife radiosurgery. Gamma Knife (Elekta Instruments Inc.) Model U was used from 1994 to 2000, Model C was used from 2000 to 2008, and Perfexion was used from 2008 to 2015. All patients were immobilized with a stereotactic head frame. The frame application was performed by a neurosurgeon utilizing four pins affixed to the cranium after the patient was provided conscious sedation by a member of the anesthesia team. Contrast-enhanced thin slice magnetic resonance imaging (MRI) of the brain was then performed for target delineation and treatment planning.

Dose prescription was at the discretion of the treating team and in general accordance with RTOG 90-05. For tumor diameter <2 cm, prescription was 20–24 Gy typically to 50% isodose line. For tumors >2 cm and <3 cm diameter, dose was generally 18 Gy to 50% isodose line. For tumors >3 cm, we typically prescribe 15 Gy to 50% isodoseline. This prescription guideline is not modified for various primary cancers including nonsmall cell lung cancer, breast cancer, melanoma, renal cell cancer, and colorectal cancer. Tumor equivalent volumes are converted using the formula for volume of a sphere, \((4/3) \pi r^3\). A 2-cm-diameter cutoff corresponds to 4.19 cc volumetric cutoff. A 3-cm-diameter cutoff corresponds to a 14.1 cc volumetric cutoff. The decision to leave BM untreated at the time of SRS was per the radiation oncologist and neurosurgeon at the time of treatment, with generally small and asymptomatic BM as lesions less likely to be treated [11].

Statistical analysis

The primary endpoint was overall survival (OS) in months. Time was calculated from the date of initial SRS treatment to the date of death. Censoring occurred at the date the patient was last known to be alive. All risk factors were defined at the time of initial SRS. Analyzed risk factors for survival included age, sex, tumor histology, performance status, graded prognostic assessment (GPA) score, recursive partitioning analysis (RPA) class, synchronous or metachronous diagnosis of BM, increase in number of BM from initial consultation to treatment, untreated BM, infratentorial BM, number of BM treated, total tumor volume (continuous and categorical <5 cc, 5–10 cc, >10 cc), and SRS dose.

Performance status was graded with the Karnofsky Performance Score (KPS) on a scale of 0 to 100. GPA was scored from 0 to 4 based on age, KPS, number of BM, and the presence of extracranial metastases [12]. RPA was scored from 1 to 3 based on age, KPS, control of primary disease, and the presence of extracranial metastases [13]. Synchronous diagnosis of BM was defined as discovery of BM within 3 months of the diagnosis of the primary cancer. Progression of BM was defined as an increase in number of identified BM between the initial diagnostic
MRI and the MRI on the day of SRS treatment. Patients were defined as having untreated BM if not all identified BM were targeted with SRS. The total tumor volume is the total volume of BM treated with SRS as measured on MRI using Leksell GammaPlan (Elekta Inc. Stockholm, Sweden) software.

Baseline variables were compared using the Wilcoxon rank sum test, Pearson’s chi-squared test, and Fisher’s exact test. OS was analyzed using the Kaplan–Meier method with significance testing with the log rank test. We performed two analyses: Analysis 1 included all patients. Analysis 2 excluded patients with prior neurosurgical resection or WBRT. All risk factors were entered into univariate analysis using the Cox proportional hazards model. Significant risk factors were further entered into multivariate analysis, except GPA and RPA scores given these measures represent a composite of other investigated factors. JMP Pro 13 (SAS Institute Cary, NC) was used to perform the analyses. All P-values were two-sided with a significance level of 0.05.

Results

Of 1017 eligible patients treated with SRS for BM between 1994 and 2015, patients with one lesion (543 patients) and patients missing survival or baseline data (83 patients) were excluded, thereby resulting in 391 patients who were included in the analysis.

All patients were analyzed regardless of prior WBRT or neurosurgical resection. Baseline characteristics are presented in Table 1. Patients with 5 or more BM had a higher rate of untreated BM and progressive BM from baseline as well as a lower GPA compared to patients with 2–4 BM. Of note, there were no significant differences in total tumor volume between the cohorts.

With a median follow-up of 7.1 months, patients with 2–4 BM (n = 314) had a median OS of 8.1 months and patients with 5 or more BM (n = 77) had a median OS of 6.2 months (P = 0.0136) (Fig. 1A). Prognostic factors with a significant effect on OS on univariate analysis included

Table 1. Baseline patient and treatment characteristics.

|                      | 2–4 (n = 314) | 5+ (n = 77) | All (n = 391) | P-value |
|----------------------|---------------|-------------|---------------|---------|
| **Age, median (range)** | 60 (13–100)   | 55 (29–100) | 59 (13–100)   | 0.11    |
| **Sex**              |               |             |               |         |
| Male                 | 172 (55%)     | 45 (58%)    | 217 (56%)     | 0.56    |
| Female               | 142 (45%)     | 32 (42%)    | 174 (44%)     |         |
| **Histology**        |               |             |               |         |
| Breast adenocarcinoma| 46 (15%)      | 9 (12%)     | 55 (14%)      | 0.26    |
| Lung NSCLC           | 59 (19%)      | 10 (13%)    | 69 (18%)      |         |
| Melanoma             | 140 (45%)     | 45 (60%)    | 185 (48%)     |         |
| Renal cell carcinoma | 25 (8%)       | 4 (5%)      | 29 (8%)       |         |
| Other                | 39 (13%)      | 7 (9%)      | 46 (12%)      |         |
| **KPS median (range)** | 90 (50–100)   | 90 (40–100) | 90 (40–100)   | 0.89    |
| **GPA, median (range)** | 2 (0–3.5)    | 1.5 (0.5–3) | 1.5 (0–3.5)   | <0.0001 |
| **RPA**              |               |             |               |         |
| Class 1              | 46 (15%)      | 6 (8%)      | 52 (14%)      | 0.20    |
| Class 2              | 247 (80%)     | 66 (89%)    | 313 (82%)     |         |
| Class 3              | 15 (5%)       | 2 (3%)      | 17 (4%)       |         |
| **Brain mets diagnosed within 3 months of primary** | 42 (16%) | 11 (17%) | 53 (16%) | 0.88 |
| Increase in # of brain mets from baseline to treatment | 101 (32%) | 47 (61%) | 148 (38%) | <0.0001 |
| **Unresected brain mets** | 48 (15%) | 19 (25%) | 67 (17%) | 0.05 |
| **Infratentorial brain mets** | 113 (36%) | 33 (43%) | 146 (37%) | 0.06 |
| **SRS dose, Gy, median (range)** | 18 (12–22) | 18 (14–20) | 18 (12–22) | 0.07 |
| **Total tumor volume, cc, median (range)** | 3.36 (0.07–36.02) | 3.53 (0.29–81.60) | 3.41 (0.071–81.60) | 0.43 |

NSCLC, Nonsmall Cell Lung Cancer; KPS, Karnofsky Performance Status; GPA, Grade Prognostic Assessment; RPA, Recursive Partitioning Analysis; mets, metastases; SRS, Stereotactic Radiosurgery.
lesion number, total tumor volume, histology, untreated BM, KPS, GPA, and RPA. Tumor volume >10 cc had a hazard ratio (HR) of 1.451 for worse OS when compared to tumor volume <5 cc \( (P = 0.010) \) (Fig. 1B). Tumor volume was also significantly associated with worse OS when analyzed as a continuous variable \( (P = 0.0314) \). Breast histology had the best OS with melanoma, lung, and other categories faring significantly worse (Fig. 1C). Lung primaries (nonsmall cell lung cancer) and other histologies (including small cell lung cancer, colorectal, prostate, ovarian) had the worst outcomes with HRs of 1.557 and 2.463, respectively, in comparison with patients with breast cancer. On multivariate analysis, only total tumor volume, KPS, and histology remained significant (Table 2).

To further analyze the relationship of tumor volume and lesion number, a standard least squared regression model was used. There was a statistically significant but weak correlation between the two \( (R^2 = 0.045, P < 0.0001) \). The number of BM only accounted for 4.5% of the variance in total tumor volume. Figure 2 displays this relationship of volume by lesion number in a box plot.

After excluding 121 patients with prior surgery \( (n = 77) \) and/or WBRT \( (n = 58) \), the difference in median OS was not significantly different on univariate \( (P = 0.0603) \) or multivariate \( (P = 0.2772) \) analysis when comparing 2–4 BM \( (n = 219) \) to 5 or more BM \( (n = 52) \) (Tables S1 and S2). Histology, KPS, GPA, RPA, and total tumor volume were significantly associated with OS on univariate analysis. On multivariate analysis, total tumor volume (both as a categorical and as a continuous variable), KPS, and histology remained significant, consistent with the primary analysis of all patients.

We further analyzed the data to attempt to develop a metric for identifying patients with the worst prognosis where consideration of best supportive care may be warranted. Given the median OS of breast cancer histology (14.72 months) versus all nonbreast histology (median OS 7.18 months; \( P = 0.006 \)), we examined all patients with nonbreast cancer. Seventy-eight patients with nonbreast histology had OS <3 months. Of these, 21 had total tumor volume >10 cc. Nine had total tumor volume >10 cc and KPS <80. We found those with total tumor volume >10 cc...
and KPS <80 had a median OS of 1.63 months compared to 7.87 months for all patients that did not meet all these criteria ($P = 0.02$). The KM survival curves based on these criteria are presented in Figure 1D.

**Discussion**

Many radiation oncologists use lesion number as an important consideration when deciding on an optimal treatment strategy of SRS versus WBRT for BM. In a survey of practicing radiation oncologists by Sandler et al., number of lesions was identified as the most important factor in decision making for selecting WBRT versus SRS—more important than performance status, size of lesions, extracranial disease status, histology, and patient convenience. Furthermore, non-CNS specialists (as defined by patient volume) were more likely to pick a lower number for the cutoff of when to no longer treat with SRS (mean 5.1 BM) versus CNS specialists (mean 8.1 BM), with a mean cutoff closer to four for minimal volume providers. Most

| Table 2. Univariate and multivariate Cox proportional hazards model of overall survival. |
|----------------------------------------|-----------------|------------------|
| Variables                              | Univariate      | Multivariate     |
|                                        | HR (95% CI)     | P-value          | HR (95% CI)     | P-value          |
| Number of BM treated                   |                 |                  |
| 2–4                                    | Ref.            | Ref.             | Ref.            | Ref.             |
| 5+                                     | 1.396 (1.062–1.810) | 0.0176    | 1.220 (0.903–1.624) | 0.1921          |
| Age                                    |                 |                  |
| ≤60 years                              | Ref.            | Ref.             | Ref.            | Ref.             |
| >60 years                              | 1.228 (0.991–1.521) | 0.0604    | 1.201 (0.957–1.505) | 0.1143          |
| Sex                                    |                 |                  |
| Male                                   | Ref.            | Ref.             | –               | –                |
| Female                                 | 0.877           | 0.2272           | –               | –                |
| Histology                              |                 |                  |
| Breast adenocarcinoma                  | Ref.            | Ref.             | Ref.            | Ref.             |
| Lung NSCLC                             | 1.557 (1.059–2.291) | 0.0236    | 1.664 (1.110–2.497) | 0.0134          |
| Melanoma                               | 1.473 (1.059–2.049) | 0.0173    | 1.422 (0.997–2.009) | 0.0397          |
| Renal cell carcinoma                   | 1.180 (0.725–1.922) | 0.5085    | 1.053 (0.641–1.730) | 0.6995          |
| Other                                  | 2.463 (1.96–3.800) | <0.0001    | 1.947 (1.231–3.079) | 0.0049          |
| KPS                                    |                 |                  |
| 90–100                                 | Ref.            | Ref.             | Ref.            | Ref.             |
| 70–80                                  | 1.533 (1.219–1.922) | 0.0003    | 1.417 (1.111–1.802) | 0.0052          |
| ≤60                                    | 2.690 (1.542–4.369) | 0.0010    | 2.340 (1.301–3.912) | 0.0059          |
| GPA                                    |                 |                  |
| 0–1                                    | Ref.            | Ref.             | –               | –                |
| 1.5–2.5                                | 0.686 (0.537–0.883) | 0.0037    | –               | –                |
| 3–4                                    | 0.514 (0.330–0.777) | 0.0013    | –               | –                |
| RPA                                    |                 |                  |
| Class 1                                | Ref.            | Ref.             | –               | –                |
| Class 2                                | 1.129 (0.827–1.579) | 0.4546    | –               | –                |
| Class 3                                | 2.394 (1.305–4.177) | 0.0059    | –               | –                |
| Synchronous BM                         | 1.139 (0.815–1.556) | 0.4351    | –               | –                |
| Increase in number of BM from baseline to treatment | 0.908 (0.725–1.131) | 0.3911    | –               | –                |
| Untreated BM                           | 1.436 (1.078–1.882) | 0.0142    | 1.321 (0.977–1.757) | 0.0701          |
| Infratentorial BM                      | 1.140 (0.915–1.415) | 0.2418    | –               | –                |
| SRS dose                               | 0.961 (0.915–1.013) | 0.1394    | –               | –                |
| SRS dose <18 Gy                        | Ref.            | Ref.             | –               | –                |
| ≥18 Gy                                 | 1.141 (0.870–1.477) | 0.3323    | –               | –                |
| Total tumor volume                     |                 |                  |
| <5 ccs                                 | Ref.            | Ref.             | Ref.            | Ref.             |
| 5–10 ccs                               | 1.223 (0.916–1.610) | 0.1682    | 1.326 (0.979–1.768) | 0.0678          |
| >10 ccs                                | 1.451 (1.094–1.900) | 0.0103    | 1.641 (1.217–2.186) | 0.0014          |

NSCLC, Non-small Cell Lung Cancer; KPS, Karnofsky Performance Status; GPA, Grade Prognostic Assessment; RPA, Recursive Partitioning Analysis; mets, metastases; SRS, Stereotactic Radiosurgery.
radiation oncologists listed four to six lesions as the cohort they found most challenging in deciding how to treat [4]. However, prior studies as well as our analysis demonstrate that although lesion number is an easily quantifiable metric, it is not necessarily the best factor in determining optimal candidacy for SRS.

In a prospective observational trial (JLGK0901), patients with 2–4 BM (n = 531) and 5 or more BM (n = 208) had equivalent median survivals of 10.8 months (P = 0.78). There was no difference in the rate of neurologic death or local recurrence between the two groups [10]. Our findings are consistent with these results. Although median OS for all patients significantly favored the 2–4 group on univariate analysis (8.13 months vs. 6.23 months, P = 0.0176), on MVA, the difference was no longer statistically significant (P = 0.2714). This result was true for all patients including those with prior WBRT and/or surgery as well as when patients were excluded that had prior WBRT and/or surgery. For patients not receiving prior WBRT and/or surgery, lesion number was not significant on univariate (P = 0.0603) or MVA (P = 0.2772).

Yamamoto et al. concluded that radiosurgery alone for patients with 5 or more BM was noninferior to outcomes with SRS alone in patients with 2–4 BM. Their group further evaluated patients with 10 or more BM treated with SRS in a propensity score case-matched analysis and found no difference between groups for OS or neurologic death as well as other measures such as local recurrence, repeat SRS for new lesions, or complications [9]. Additional evidence comes from prior retrospective series including Chang et al. [14], who found no difference in regard to outcomes after SRS for patients with 1–5, 6–10, 11–15 or even more metastases.

Tumor volume may be more important in terms of prognostication than lesion number. In the current series, tumor volume >10 cc was associated with worse OS (HR = 1.451). Multiple prior series have found similar results regarding the association between increasing tumor volume and worse outcomes. Bhatnagar et al., Likhacheva et al., and Baschnagel et al., demonstrated that tumor volume was statistically significantly associated with OS while number of BM was not [15–17]. Interestingly, this was true in our series of all patients and excluding patients with prior WBRT or surgery. Cumulative tumor volume was likewise significantly associated with worse survival on univariate analysis in JLGK0901.

Secondary factors including female sex, age <65, KPS ≥80, stable extracranial disease, and the absence of neurologic symptoms were significantly associated with longer OS in JLGK0901 [10]. In our analysis, histology and KPS (along with tumor volume) were significantly associated with OS on MVA. These factors have been studied in prior series and components utilized in the graded prognostic assessment and in nomograms. While lesion number is often a factor, tumor volume is rarely included in these scoring systems [18].

To further investigate the association of the interplay of number of BM and volume, we looked at the correlation between the two. While increasing number of BM was significantly correlated with tumor volume, it accounted for only 5% of the variance. Additionally, we identified a high-risk cohort, namely histology other than breast cancer, tumor volume >10 cc, and KPS <80. These patients had a median OS of <2 months.

This study is limited by its retrospective nature and the limited scope of patient data, such as lack of information regarding systemic therapies. These data are subject to inherent biases including selection bias in that the 5 or more BM group could represent a select and more favorable cohort. However, the intent of this analysis was to look at patients in a clinical setting treated at the discretion of the consulting radiation oncologist, and the groups were well balanced with the exception of GPA as described above. Patients treated over the course of two decades were analyzed, representing a heterogeneous group with many changes in overall approaches to oncologic care throughout this time period. However, these results of patients treated at a single institution over 20 years have practical implications for current management of the increasingly common patient presenting with multiple BM, especially in the absence of a randomized trial. Arbitrarily using a cutoff of 5 or more metastases is not warranted based on this data and should not exclude patients from radiosurgery, nor should prior WBRT or neurosurgical resection.

Current guidelines have clearly delineated recommendations for patients with 4 or fewer metastases but not for patients with 5 or more lesions in regard to SRS [19, 20]. A single institution phase III randomized trial (NCT01592968) currently enrolling patients with 4 or
more BM to SRS versus WBRT will ideally provide level 1 evidence regarding optimal management [21].

Ultimately, the decision to treat a patient with more than 4 BM with SRS depends on a number of clinical and pathologic factors, including systemic therapeutic options, prognosis, and the patient’s goals of care. These factors should be discussed in a multidisciplinary tumor board setting when possible. Tumor volume in conjunction with other clinical and pathologic features is likely more important in terms of prognostication than lesion number alone, and has recently been shown to improve prognostic models including disease-specific GPA [22–24].

With the increasingly common use of targeted agents, delays in systemic therapy secondary to WBRT could ultimately be detrimental to a patient’s outcome. Nevertheless, even in the setting of targeted agents, radiotherapy remains an important treatment for patients with BM and could impact OS [25]. Furthermore, immunotherapy and targeted agents may lead to better tumor control and reduce distant brain failure, rendering SRS more impactful [26]. Finally, with close surveillance, patients that have regional failure after SRS can undergo effective salvage SRS with low morbidity, providing further rationale for the upfront use of SRS.

**Conclusions**

Patients with 5 or more BM treated with SRS have comparable OS to those with 2–4 BM, regardless of prior WBRT or surgery, and remain good candidates for SRS based on the results of this study. While number of lesions may be prognostic, total tumor volume may be a more important factor in determining OS. Given the side effects associated with WBRT and equivalent outcomes with SRS alone, our analysis supports offering SRS alone to select patients with 5 or more BM with total tumor volume <10 cc in clinical practice.

**Acknowledgment**

We gratefully acknowledge the Kozak Family for providing support for publications costs for this research work.

**Conflict of Interest**

Eric L. Chang discloses that he received speaker’s honorarium from Brainlab.

**References**

1. Aoyama, H., H. Shirato, M. Tago, K. Nakagawa, T. Toyoda, K. Hatano, et al. 2006. Stereotactic radiosurgery plus whole-brain radiation therapy vs stereotactic radiosurgery alone for treatment of brain metastases: a randomized controlled trial. JAMA 295:2483–2491.
2. Yau, T., C. Swanton, S. Chua, A. Sue, G. Walsh, A. Rostom, et al. 2006. Incidence, pattern and timing of brain metastases among patients with advanced breast cancer treated with trastuzumab. Acta Oncol. 45:196–201.
3. Li, J., and P. D. Brown. 2017. The diminishing role of whole-brain radiation therapy in the treatment of brain metastases. JAMA Oncol. 3:1023–1024.
4. Sandler, K. A., N. Shaverdian, R. R. Cook, A. U. Kishan, C. R. King, I. Yang, et al. 2017. Treatment trends for patients with brain metastases: Does practice reflect the data? Cancer 123:2274–2282.
5. Sahgal, A., H. Aoyama, M. Kocher, B. Neupane, S. Collette, M. Tago, et al. 2015. Phase 3 trials of stereotactic radiosurgery with or without whole-brain radiation therapy for 1 to 4 brain metastases: individual patient data meta-analysis. Int. J. Radiat. Oncol. Biol. Phys. 91:710–717.
6. Brown, P. D., K. V. Ballman, J. Cerhan, S. K. Anderson, X. W. Carrero, A. C. Whitton, et al. 2016. N107C/CEC.3: a phase III trial of post-operative stereotactic radiosurgery (SRS) compared with whole brain radiotherapy (WBRT) for resected metastatic brain disease. Int. J. Rad. Oncol. Biol. Phys. 96:937.
7. Brown, P. D., K. Jaeckle, K. V. Ballman, E. Farace, J. H. Cerhan, S. K. Anderson, et al. 2016. Effect of radiosurgery alone vs radiosurgery with whole brain radiation therapy on cognitive function in patients with 1 to 3 brain metastases: a randomized clinical trial. JAMA 316:401–409.
8. Chang, E. L., J. S. Wefel, K. R. Hess, P. K. Allen, F. F. Lang, D. G. Korneguth, et al. 2009. Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation: a randomised controlled trial. Lancet Oncol. 10:1037–1044.
9. Yamamoto, M., T. Kawabe, Y. Sato, Y. Higuchi, T. Nariai, S. Watanabe, et al. 2014. Stereotactic radiosurgery for patients with multiple brain metastases: a case-matched study comparing treatment results for patients with 2–9 versus 10 or more tumors. J. Neurosurg. 121(Suppl):16–25.
10. Yamamoto, M., T. Serizawa, T. Shuto, A. Akabane, Y. Higuchi, J. Kawagishi, et al. 2014. Stereotactic radiosurgery for patients with multiple brain metastases (JLGK0901): a multi-institutional prospective observational study. Lancet Oncol. 15:387–395.
11. Shaw, E., C. Scott, L. Souhami, R. Dinapoli, R. Kline, J. Loefller, et al. 2000. Single dose radiosurgical treatment of recurrent previously irradiated primary brain tumors and brain metastases: final report of RTOG protocol 90-05. Int. J. Radiat. Oncol. Biol. Phys. 47:291–298.
12. Sperduto, P. W., S. T. Chao, P. K. Sneed, X. Luo, J. Suh, D. Roberge, et al. 2010. Diagnosis-specific prognostic factors, indexes, and treatment outcomes for patients with newly diagnosed brain metastases: a multi-institutional analysis of 4,259 patients. Int. J. Radiat. Oncol. Biol. Phys. 77:655–661.

13. Gaspar, L., C. Scott, M. Rotman, S. Asbell, T. Phillips, T. Wasserman, et al. 1997. Recursive partitioning analysis (RPA) of prognostic factors in three Radiation Therapy Oncology Group (RTOG) brain metastases trials. Int. J. Radiat. Oncol. Biol. Phys. 37:745–751.

14. Chang, W. S., H. Y. Kim, J. W. Chang, Y. G. Park, and J. H. Chang. 2010. Analysis of radiosurgical results in patients with brain metastases according to the number of brain lesions: is stereotactic radiosurgery effective for multiple brain metastases? J. Neurosurg. 113(Suppl):73–78.

15. Bhatnagar, A. K., J. C. Flickinger, D. Kondziolka, and L. D. Lunsford. 2006. Stereotactic radiosurgery for four or more intracranial metastases. Int. J. Radiat. Oncol. Biol. Phys. 64:898–903.

16. Likhacheva, A., C. C. Pinnix, N. R. Parikh, P. K. Allen, M. F. McAleer, M. S. Chiu, et al. 2013. Predictors of survival in contemporary practice after initial radiosurgery for brain metastases. Int. J. Radiat. Oncol. Biol. Phys. 85:656–661.

17. Baschnagel, A. M., K. D. Meyer, P. Y. Chen, D. J. Krauss, R. E. Olson, D. R. Pieper, et al. 2013. Tumor volume as a predictor of survival and local control in patients with brain metastases treated with Gamma Knife surgery. J. Neurosurg. 119:1139–1144.

18. Gorovets, D., D. Ayala-Peacock, D. J. Tybor, P. Rava, D. Ebner, D. Cielo, et al. 2017. Multi-institutional nomogram predicting survival free from salvage whole brain radiation after radiosurgery in patients with brain metastases. Int. J. Radiat. Oncol. Biol. Phys. 97:246–253.

19. National Comprehensive Cancer Network. Central Nervous System Cancers. Available at: https://www.nccn.org/professionals/physician_gls/pdf/cns.pdf

20. Tsao, M. N., D. Rades, A. Wirth, S. S. Lo, B. L. Danielson, L. E. Gaspar, et al. 2012. Radiotherapeutic and surgical management for newly diagnosed brain metastasis(es): An American Society for Radiation Oncology evidence-based guideline. Pract. Radiat. Oncol. 2:210–225.

21. Li, J. E. A. A Prospective Phase III Randomized Trial to Compare Stereotactic Radiosurgery Versus Whole Brain Radiation Therapy for >/= 4 Newly Diagnosed Non-Melanoma Brain Metastases. Available at: https://clinicaltrials.gov/ct2/show/NCT01592968 (accessed March 19, 2017).

22. Bian, S. X., D. Routman, J. Liu, D. Yang, S. Groshen, G. Zada, et al. 2016. Prognostic factors for melanoma brain metastases treated with stereotactic radiosurgery. J. Neurosurg. 125(Suppl 1):31–39.

23. Ali, M. A., B. R. Hirshman, B. Wilson, A. J. Schupper, R. Joshi, J. A. Proudfoot, et al. 2017. Improving the prognostic value of disease specific Graded Prognostic Assessment (ds-GPA) model for renal cell carcinoma by incorporation of Cumulative Intracranial Tumor Volume (CITV). World Neurosurg. 108:151–156.

24. Hirshman, B. R., B. Wilson, M. A. Ali, J. A. Proudfoot, T. Koiso, O. Nagano, et al. 2017. Superior prognostic value of cumulative intracranial tumor volume relative to largest intracranial tumor volume stereotactic radiosurgery-treated brain metastasis patients. Neurosurgery. 2017 Jun 27. DOI: 10.1093/neuros/nyx225. [Epub ahead of print]

25. Magnuson, W. J., N. H. Lester-Coll, A. J. Wu, T. J. Yang, N. A. Lockney, N. K. Gerber, et al. 2017. Management of brain metastases in tyrosine kinase inhibitor-naive epidermal growth factor receptor-mutant non-small-cell lung cancer: a retrospective multi-institutional analysis. J. Clin. Oncol. 35:1070–1077.

26. Peters, S., D. R. Camidge, A. T. Shaw, S. Gadgeel, J. S. Ahn, et al. 2017. Alectinib versus crizotinib in untreated ALK-positive non-small-cell lung cancer. N. Engl. J. Med. 377:829–838.

Supporting Information

Additional supporting information may be found in the online version of this article:

Table S1. Baseline patient and treatment characteristics, after excluding patients receiving prior surgery or WBRT.

Table S2. Univariate and multivariate Cox proportional hazards model of overall survival, after excluding patients receiving prior surgery or WBRT.